Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab Dose Escalation in iMCD
NCT04838860Phase 2Terminated
- Sponsor
- Recordati SpA
- Start
- Mar 2021
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of siltuximab in idiopathic multicentric Castleman disease (iMCD) (2 arms), sponsored by Recordati SpA. Primary endpoint: Clinical Benefit Response at 12 weeks. Started Mar 2021; status: terminated.
02
Drugs
siltuximab
03
Conditions
idiopathic multicentric Castleman disease (iMCD)
Beyond the preview
Go deeper on NCT04838860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04838860.